Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.
Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.